HOME >> MEDICINE >> NEWS
Prescribing inconsistencies in prostate cancer treatment in the UK when using LHRHAs

London, 12 December 2006 -- Eighty-four percent of GPs and 76 percent of specialists (uro-oncologists or urologists) agree that there is a significant legal risk associated with off-label prescribing in prostate cancer when there is a licensed alternative available, according to new survey data released today.[1] Despite this, 46 percent of specialists felt that primary care commonly changes the recommended Leutinising Hormone-Replacement Hormone agonist (LHRHa) when referring management of patients to the community.

The Need for a Data Driven Solution

The data show that nearly all (92 percent) specialists, GPs, oncology pharmacists and specialist urology nurses surveyed agree that patients should receive an LHRHa with supporting clinical evidence wherever possible. Zoladex (goserelin) is licensed for all stages of prostate cancer suitable for hormonal manipulation.[2] Also, it is the only LHRHa with a proven survival benefit in adjuvant treatment in high risk localised disease and in adjuvant treatment of locally advanced prostate cancer when compared to surgery or radiotherapy alone.[3],[4],[5] However, when asked to differentiate between goserelin and another LHRHa not licensed for all stages of prostate cancer suitable for hormone manipulation, 75 percent of GPs and 42 percent of specialists felt in their view that the clinical evidence was the same.

Commenting on the data, Dr Heather Payne, Consultant Clinical Oncologist in Urological Tumours, University College Hospital, London stated: "Prostate cancer is a complicated disease and can be treated in several different ways. Depending on the stage of the cancer, a clear understanding of the supporting clinical evidence for treatments should guide prescribing decisions. As healthcare professionals, we need to provide patients with the best evidence-based treatment and care at all times."

Secondary and Primary Care Divide

Although 76 percent
'"/>

Contact: Marianne Thrall
mthrall@hillandknowlton.com
20-741-33733
Hill and Knowlton
12-Dec-2006


Page: 1 2 3

Related medicine news :

1. Prescribing information for kidney disease far too vague
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. African-American men understimate risk of prostate cancer
5. Treatment for early prostate cancer associated with type of specialist seen
6. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
7. Flaxseed stunts the growth of prostate tumors
8. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
9. Radium-223: An alternative treatment for prostate cancer
10. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
11. New prostate cancer clinical guidelines to be released

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/9/2018)... COSTA MESA, Calif. (PRWEB) , ... August 09, ... ... treatment, officially announces LegitScript certification. LegitScript is a new verification process that substance ... Longridge said, “Being LegitScript certified means we can reach more people to help.” ...
(Date:8/9/2018)... ... August 09, 2018 , ... Thanks to the ... company’s independent distributors, customers, and employees, the newly established Isagenix Legacy Foundation ... $2 million goal. 100 percent of the donations will fund grants to nonprofit ...
(Date:8/7/2018)... ... 07, 2018 , ... Today Springfield Creamery added six new ... cream-on-top-style yogurts are made with milk from grass-fed cows who enjoy a diet ... acids. Nancy’s sources the milk from organic family-owned farms, all within 60 miles ...
(Date:8/3/2018)... ... ... On August 2, 2018 the JPML ordered that the Zostavax MDL be ... has been litigating Zostavax injuries since 2011. , On ... the thousands of people injured by Zostavax, a vaccine given to adults to prevent ...
(Date:8/2/2018)... ... 02, 2018 , ... Dr. Srini Pillay , best-selling author of ... people could care less, demonstrating a “whatever” attitude toward life, people, and situations around ... one often overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition ...
Breaking Medicine News(10 mins):
(Date:8/9/2018)... (PRWEB) , ... August 09, 2018 , ... ... CBD Day with Charlotte-area company cbdMD named the exclusive sponsor. , “We’re honored ... exciting to see such public embrace for CBD on a national level,” said ...
(Date:8/7/2018)... ... August 07, 2018 , ... Commissioner Gottlieb’s FDA:, Analysis of First ... – 3:00 p.m. ET, http://www.fdanews.com/commissionergottliebsfda , Under Commissioner Scott Gottlieb, changes ... have benefited, some may have gotten hurt. , And Gottlieb is just getting started. ...
(Date:8/7/2018)... PLEASANTON, Calif. (PRWEB) , ... ... ... Chief Executive Officer, today announced the appointment of Richard A. Stark to assume the role of Sanarus ... will apply his 20+ years of strategic development, marketing and sales experience in medical ...
Breaking Medicine Technology:
Cached News: